Repligen Corporation
Repligen Corp. is a U.S.-based life sciences company focused on bioprocessing technologies and systems used in the manufacture of biological drugs. Its portfolio spans filtration, chromatography, process analytics and proteins products sold to biopharmaceutical companies, CDMOs and other life science customers worldwide.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueSingle-use and reusable filtration technologies used in upstream and downstream bioprocessing.
Purification products including columns and related chromatography systems for biologics manufacturing.
Instrumentation and desktop PAT tools used to monitor and optimize bioprocess operations.
Affinity ligands and protein-based products used in purification and separation workflows.
Products
Reported · share of revenue- Filtration Products54.6 %
- Chromatography Products20.8 %
- Proteins Products13.2 %
- Process Analytics Products11.0 %
- Other Products0.4 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Repligen sells primarily to global biopharmaceutical companies, CDMOs and other life science companies that manufacture biologic drugs. These customers buy Repligen’s products to improve process efficiency, reduce contamination risk, and support development and production of monoclonal antibodies, recombinant proteins, vaccines and advanced therapies.
Buy filtration, chromatography and analytics tools for biologics production and process optimization.
Buy integrated bioprocessing products to support outsourced manufacturing for multiple clients.
Buy across franchises to build connected unit operations and complete bioprocess workflows.
Buy selected products and technologies where bioprocessing or related applications overlap.
Buy certain products for research and development workflows rather than commercial manufacturing.
Strategy
Repligen’s strategy is to broaden its bioprocessing platform across filtration, chromatography, process analytics and proteins so customers can source more of the workflow from one supplier. The company also emphasizes integrated solutions, internal R&D and acquisitions to add differentiated technologies and deepen its position in biologics manufacturing.
Customers increasingly want connected unit operations rather than standalone tools.
Actionable process data helps customers improve development and manufacturing efficiency.
Acquired technologies can extend the portfolio and accelerate market access.
Global support and reliable supply are critical in regulated biologics production.
Geography
Repligen operates globally from its headquarters in Waltham, Massachusetts, with offices and manufacturing sites in the United States, Europe and Asia. Revenue is geographically diversified, with North America representing 49%, Europe 34% and APAC plus Rest of World 17% in 2025, reflecting broad exposure to global biologics manufacturing.
Risks
Repligen faces intense competition in a fast-changing bioprocessing market, where new technologies can displace existing products and customers may switch suppliers. Its global footprint also creates exposure to foreign exchange, tariffs, supply chain inflation, partner dependence, cybersecurity incidents and the risk that acquired technologies or intangible assets do not deliver expected value.
- Intense bioprocessing competitionImpact: HighLikelihood: Medium
New product introductions and alternative technologies can reduce demand for existing products.
Exposure - Acquisition and goodwill impairmentImpact: HighLikelihood: Medium
Acquired technology and customer relationships may not generate expected returns.
Exposure: Purchased intangibles and goodwill
- Foreign exchange volatilityImpact: MediumLikelihood: Medium
A large share of revenue and expenses is denominated outside the U.S. dollar.
Exposure: Europe and APAC operations
- Supply chain inflation and tariffsImpact: MediumLikelihood: Medium
Raw materials, logistics and trade actions can raise costs or disrupt deliveries.
Exposure: Global manufacturing and sourcing
- Cybersecurity and data incidentsImpact: MediumLikelihood: Medium
Sensitive employee, IP and vendor data are stored across internal and third-party systems.
Exposure: IT systems and vendor networks
Accounting
Judgemental itemsRevenue includes product sales plus variable royalties tied to partner activity.
Impact: Can create quarter-to-quarter variability in reported revenue
Acquisitions have created significant developed technology and customer relationship assets.
Impact: Impairment charges could materially reduce earnings and equity
A large share of revenue and expenses is generated outside the U.S.
Impact: Affects comparability of reported results across periods
Recent and prior acquisitions add fair value estimates for assets and liabilities.
Impact: Can affect amortization expense and future impairment risk
Similar listed companies
Publicly listed companies with a comparable business focus.
Replimune Group, Inc.
REPL · Biological Products, (No Diagnostic Substances)
Revvity, Inc
RVTY · Laboratory Analytical Instruments
Revvity is a U.S.-based health science company that develops instruments, software, reagents, and services used across research, screening, diagnostics, and reproductive health workflows.
BioLife Solutions, Inc
BLFS · Electromedical & Electrotherapeutic Apparatus
Bioregenx, Inc.
BRGX · Services-Computer Programming, Data Processing, Etc.
Bio-Rad Laboratories, Inc
BIO · Laboratory Analytical Instruments
Bio-Rad Laboratories is a U.S.-based multinational that develops, manufactures, and sells tools used in life science research and clinical diagnostics.
Immuneering Corp
IMRX · Pharmaceutical Preparations
Immuneering Corp is a clinical-stage biotechnology company focused on developing oncology therapies, with an emphasis on MAPK pathway cancers and biomarker-driven patient selection.
Last updated: 24/09/2026